Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Alnylam Pharma (ALNY) Prices 5.6M Share Common Offering at $125/Sh
-
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
-
Chardan Capital Markets Downgrades Intellia Therapeutics (NTLA) to Neutral
-
Alnylam Pharma (ALNY): Cutting PT to $124 - Chardan
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $131 at Chardan Capital Markets
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $110 at Chardan Capital Markets
-
Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets
-
Alnylam Pharmaceuticals (ALNY) PT Raised 41% at Chardan Capital Markets to $97
-
Chardan Capital Markets Positive on Alnylam (ALNY) as ASH Data Reinforces Potential for RNAi Across Hemophilia and AIP
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $89 at Chardan Capital Markets Following Arrowhead's RNAi Program Discontinuations
-
Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
-
Chardan Capital Markets Starts Alnylam Pharmaceuticals (ALNY) at Buy
-
Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan Capital
-
Chardan Trims PT on Esperion (ESPR) to $36 as Negatives Continue Increasing